Literature DB >> 23168380

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L.

Gustavo E Chavarria1, Michael R Horsman, Wara M Arispe, G D Kishore Kumar, Shen-En Chen, Tracy E Strecker, Erica N Parker, David J Chaplin, Kevin G Pinney, Mary Lynn Trawick.   

Abstract

Kinetic analysis of the mode of inhibition of cathepsin L by KGP94, a lead compound from a privileged library of functionalized benzophenone thiosemicarbazone derivatives, demonstrated that it is a time-dependent, reversible, and competitive inhibitor of the enzyme. These results are consistent with the formation of a transient covalent bond, and are supported by molecular modeling that places the thiocarbonyl of the inhibitor in proximity to the thiolate moiety of the enzyme active site Cys25. KGP94 significantly decreased the activity of cathepsin L toward human type I collagen, and impeded both migration and invasion of MDA-MB-231 human breast cancer cells. Growth retardation was achieved in vivo against both recently implanted and established tumours using a C3H mouse mammary carcinoma model.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23168380     DOI: 10.1016/j.ejmech.2012.10.039

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.

Authors:  Dhivya R Sudhan; Maria B Rabaglino; Charles E Wood; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2016-04-07       Impact factor: 5.150

3.  Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Authors:  Erica N Parker; Jiangli Song; G D Kishore Kumar; Samuel O Odutola; Gustavo E Chavarria; Amanda K Charlton-Sevcik; Tracy E Strecker; Ashleigh L Barnes; Dhivya R Sudhan; Thomas R Wittenborn; Dietmar W Siemann; Michael R Horsman; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2015-09-25       Impact factor: 3.641

4.  Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2013-06-09       Impact factor: 5.150

5.  Mechanistic insights into mode of action of novel natural cathepsin L inhibitors.

Authors:  Chetna Tyagi; Sonam Grover; Jaspreet Dhanjal; Sukriti Goyal; Manisha Goyal; Abhinav Grover
Journal:  BMC Genomics       Date:  2013-12-09       Impact factor: 3.969

Review 6.  Targeting lysosomes in human disease: from basic research to clinical applications.

Authors:  Mengdie Cao; Xiangyuan Luo; Kongming Wu; Xingxing He
Journal:  Signal Transduct Target Ther       Date:  2021-11-08

7.  G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound.

Authors:  Maia Cabrera; Natalia Gomez; Federico Remes Lenicov; Emiliana Echeverría; Carina Shayo; Albertina Moglioni; Natalia Fernández; Carlos Davio
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

8.  Cathepsin L secretion by host and neoplastic cells potentiates invasion.

Authors:  Samantha S Dykes; Henrietta O Fasanya; Dietmar W Siemann
Journal:  Oncotarget       Date:  2019-09-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.